 AORTIC ANEURYSM, FAMILIAL THORACIC 7
|
BREAST CANCER, SUSCEPTIBILITY TO
|
CARDIOFACIOCUTANEOUS SYNDROME 3
|
CARDIOFACIOCUTANEOUS SYNDROME 4
|
CHRONIC MYELOID LEUKEMIA, RESISTANT TO IMATINIB
|
COFFIN-LOWRY SYNDROME
|
COFFIN-LOWRY SYNDROME, MILD
|
COWDEN DISEASE 6
|
DIABETES MELLITUS, TYPE II
|
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 2
|
EPILEPTIC ENCEPHALOPATHY, EARLY INFANTILE, 2 (EIEE2)
|
FG SYNDROME 4
|
GLYCOGEN STORAGE DISEASE 9C (GSD9C)
|
GLYCOGEN STORAGE DISEASE IXC
|
HEPATOCELLULAR CARCINOMA, CHILDHOOD TYPE, SOMATIC
|
LEUKEMIA, PHILADELPHIA CHROMOSOME-POSITIVE, RESISTANT TO IMATINIB
|
MALFORMATIONS
|
MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS SYNDROME
|
MELANOMA, MALIGNANT, SOMATIC
|
MENTAL RETARDATION AND MICROCEPHALY WITH PONTINE AND CEREBELLAR HYPOPLASIA
|
MENTAL RETARDATION AND MICROCEPHALY WITH PONTINE AND CEREBELLAR HYPOPLASIA (MICPCH)
|
MENTAL RETARDATION, X-LINKED 19
|
MENTAL RETARDATION, X-LINKED 30
|
MENTAL RETARDATION, X-LINKED, WITH NYSTAGMUS
|
NEPHRONOPHTHISIS 9 (NPHP9)
|
OGUCHI DISEASE 2
|
PANCREATIC CANCER, SOMATIC
|
PEUTZ-JEGHERS SYNDROME
|
PEUTZ-JEGHERS SYNDROME (PJS)
|
PROSTATE CANCER, PROGRESSION AND METASTASIS OF
|
PROSTATE CANCER, SOMATIC
|
RENAL CELL CARCINOMA, PAPILLARY, 1
|
RENAL CELL CARCINOMA, PAPILLARY, 1, SOMATIC
|
SHORT RIB-POLYDACTYLY SYNDROME 2A (SRPS2A)
|
SHORT RIB-POLYDACTYLY SYNDROME, TYPE IIA
|
SPERMATOGENIC FAILURE 5
|
SPINOCEREBELLAR ATAXIA 14
|
T-CELL IMMUNODEFICIENCY, RECURRENT INFECTIONS, AUTOIMMUNITY, AND CARDIAC
|
TESTICULAR GERM CELL TUMOR (TGCT)
|
TESTICULAR TUMOR, SOMATIC
|
THROMBOCYTOPENIA 2
|
VARIANT OF UNKNOWN SIGNIFICANCE
|
Catalytic domain of the Protein Serine/Threonine Kinase, Rho-associated coiled-coil containing protein kinase 2. Serine/Threonine Kinases (STKs), ROCK subfamily, ROCK2 (or ROK-alpha) isoform, catalytic (c) domain. STKs catalyze the transfer of the gamma-phosphoryl group from ATP to serine/threonine residues on protein substrates. The ROCK subfamily is part of a larger superfamily that includes the catalytic domains of other protein STKs, protein tyrosine kinases, RIO kinases, aminoglycoside phosphotransferase, choline kinase, and phosphoinositide 3-kinase. ROCK contains an N-terminal extension, a catalytic kinase domain, and a C-terminal extension, which contains a coiled-coil region encompassing a Rho-binding domain (RBD) and a pleckstrin homology (PH) domain. ROCK is auto-inhibited by the RBD and PH domain interacting with the catalytic domain, and is activated via interaction with Rho GTPases. ROCK2 was the first identified target of activated RhoA, and was found to play a role in stress fiber and focal adhesion formation. It is prominently expressed in the brain, heart, and skeletal muscles. It is implicated in vascular and neurological disorders, such as hypertension and vasospasm of the coronary and cerebral arteries. ROCK2 is also activated by caspase-2 cleavage, resulting in thrombin-induced microparticle generation in response to cell activation. Mice deficient in ROCK2 show intrauterine growth retardation and embryonic lethality because of placental dysfunction.
No pairwise interactions are available for this conserved domain.
